Immunosuppressive agents in dermatology: An update

Dermatologic Clinics

Volumn 16, Issue 2, 1998, Pages 235-251

  Dutz, J P ^a   Ho, V C ^a  

^a Skin Care Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; BULLOUS SKIN DISEASE; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; ECZEMA; GENETIC POLYMORPHISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MEGALOCYTOSIS; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE;

EID: 0031949261     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70006-1     Document Type: Article

References (141)

1. W. Aberer E.C. Wolff-Schreiner G. Stingl Azathioprine in the treatment of pemphigus vulgaris J Am Acad Dermatol 16 1987 527 533
2. A. Al-Awadhi P. Dale R.J. McKendry Pancytopenia associated with low dose methotrexate therapy. A regional survey J Rheumatol 20 1993 1121 1125
3. S.A. Alkins J.C. Byrd S.K. Morgan Anaphylactoid reactions to methotrexate [Review] Cancer 77 1996 2123 2126
4. W.K. Andersen D.S. Feingold Adverse drug interactions clinically important for the dermatologist Arch Dermatol 131 1995 468 473
5. A. Anstey Management of immunobullous disorders: The clinical significance of interindividual variation in azathioprine metabolism Clin Exp Dermatol 21 1997 244 251
6. R. Auerbach Psoriasis symposium Methotrexate Semin Dermatol 11 1992 23 29
7. G.L. Baker L.E. Kahl B.C. Zee Malignancy following treatment of rheumatoid arthritis with cyclophosphamide; long-term case-control follow-up study Am J Med 83 1987 1 9
8. F.M. Balis J. Mirro G.H. Reaman Pharmacokinetics of subcutaneous methotrexate J Clin Oncol 6 1988 1882 1886
9. J.A. Baltus The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow up Ann Rheum Dis 42 1983 368 373
10. B. Bannwarth L. Labat Y. Moride Methotrexate in rheumatoid arthritis, an update Drugs 47 1994 25 50
11. B. Bannwarth F. Pehourcq T. Schaeverbeke Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis [Review] Clin Pharmacokin 30 1996 194 210
12. C.G. Beckett P. Hill K.R. Hine Leucocytoclastic vasculitis in a patient with azathioprine hypersensitivity [Review] Postgrad Med J 72 1996 437 438
13. J. Berth-Jones R.A. Graham-Brown R. Marks Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis Br J Dermatol 136 1997 76 81
14. J. Berth-Jones S.G. Smith R.A.C. Graham-Brown Benign familial chronic pemphigus (Hailey-Hailey disease) responds to cyclosporin Clin Exp Dermatol 20 1995 70 72
15. J. Berth-Jones S.G. Smith R.A.C. Graham-Brown Nodular prurigo responds to cyclosporin Br J Dermatol 132 1995 795 799
16. J. Berth-Jones J.J. Voorhees Consensus conference on cyclosporin A microemulsion for psoriasis Br J Dermatol 135 1996 775 777
17. R. Blanco T.V. Martinez G.M. Gonzalez Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. [Review] Arthritis Rheum 39 1996 1016 1020
18. A.M.T. Boerbooms P.J.S.M. Kerstens J.W.A. van Loenhout Infections during low-dose methotrexate treatment in rheumatoid arthritis Sem Arthritis Rheum 24 1995 411 421
19. M. Boffa R. Chalmers N. Haboubi Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal Br J Dermatol 133 1995 774 778
20. M.J. Boffa A. Smith R.J. Chalmers Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients Br J Dermatol 135 1996 538 544
21. J.F. Bourke J.J. Berth J. Holder A new microemulsion formulation of cyclosporin (Neoral) is effective in the treatment of cyclosporin-resistant dermatoses Br J Dermatol 134 1996 777 779
22. B.J. Bouwes D.R. Hardie A. Green The risk of skin cancer in renal transplant recipients in Queensland, Australia A follow-up study Transplantation 61 1996 715 721
23. P.P. Bradley G.D. Warden J.G. Maxwell Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole Ann Int Med 93 1980 560 562
24. G.G. Briggs R.K. Freeman S.J. Yaffe Drugs in pregnancy and lactation, a reference guide to fetal and neonatal risk 4th ed 1994 Williams & Wilkins Baltimore 79a 82a
25. D.A. Buckley S. Rogers Cyclosporin-responsive hidradenitis suppurativa J R Soc Med 88 1995 289P 290P
26. J.C. Bystryn N.M. Steinman The adjuvant therapy of pemphigus. An update [Review] Arch Dermatol 132 1996 203 212
27. R.D.R. Camp S. Reitamo P.S. Friedman Cyclosporin A in severe, therapy-resistant atopic dermatitis: Report of an international workshop Br J Dermatol 129 1993 127 220
28. P.J. Carson A. Hameed A.R. Ahmed Influence of treatment on the clinical course of pemphigus vulgaris J Am Acad Dermatol 34 1996 645 652
29. S.P. Castle M.M. Mather S. Bennion Chronic herpes gestationis and antiphospholipid antibody syndrome successfully treated with cyclophosphamide J Am Acad Dermatol 34 1996 333 336
30. P. Chocair J. Duley H. Simmonds The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant patients Transplantation 53 1992 1051 1056
31. Chren M.-M. C.M. Casserly K.C. Strange Folic acid supplementation with methotrexate therapy: What benefit if any? J Am Acad Dermatol 31 1994 689
32. F. Chrysomallis D. Ioannides A. Teknetzis Treatment of oral pemphigus vulgaris Int J Dermatol 33 1994 803 807
33. B.D. Clayton J.L. Jorizzo M.G. Hitchcock Adult pityriasis rubra pilaris: A 10 year case series J Am Acad Dermatol 36 1997 959 964
34. M.R. Compton D.L. Crosby Rhabdomyolysis associated with azathioprine hypersensitivity syndrome [letter] Arch Dermatol 132 1996 1254 1255
35. C. Confavreux P. Saddier J. Grimaud Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study Neurology 46 1996 1607 1612
36. N.M. Craig A.M. Putterman R.K. Roenigk Multiple periorbital cutaneous myxomas progressing to scleromyxedema J Am Acad Dermatol 34 1996 928 930
37. B.N. Cronstein Molecular therapeutics. Methotrexate and its mechanism of action [Review] Arthritis Rheum 39 1996 1951 1960
38. B.N. Cronstein D. Naime E. Ostad The antiinflammatory mechanism of methotrexate J Clin Invest 92 1993 2675 2682
39. D. Cummins M. Sekar O. Halil Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation Transplantation 61 1996 1661 1662
40. S.M. Dawisha C.H. Yarboro E.M. Vaughan Out-patient monthly oral bolus cyclophosphamide therapy in systemic lupus erythematosus J Rheumatol 23 1996 273 278
41. A.E. Donnenfeld A. Pastuszak J.S. Noah Methotrexate exposure prior and during pregnancy (letter) Teratology 49 1994 79 81
42. P. Duhra Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis J Am Acad Dermatol 28 1993 466 469
43. J. Dutz V. Ho Immunosuppressive agents in skin disorders Clin Immunother 5 1996 268 293
44. P. Erkko H. Granlund M. Nuutinen Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis Br J Dermatol 136 1997 82 88
45. W.V. Fairchild C.R. Spence H.D. Soloman The incidence of bladder cancer after cyclophosphamide therapy J Urol 122 1979 163 164
46. D. Faulds K.L. Goa P. Benfield Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders Drugs 45 1993 953 1040
47. G. Feutren K. Abeywickrama D. Friend Renal function and blood pressure in psoriatic patients treated with cyclosporin A Br J Dermatol 122 Suppl 36 1990 57 69
48. G. Feutren M. Mihatsch Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases N Engl J Med 326 1992 1654 1660
49. R. Filotico G.A. Vena C. Coviello Cyclosporine in the treatment of generalized granuloma annulare J Am Acad Dermatol 30 1994 487 488
50. L. Fraiser S. Kanekal J. Kehrer Cyclophosphamide toxicity. Characterising and avoiding the problem Drugs 42 1991 781 791
51. N. Franck B. Amor X. Ayral Multicentric reticulohistiocytosis and methotrexate J Am Acad Dermatol 33 1995 524 525
52. N.G. Frangogiannis I. Boridy M. Mazhar Cyclophosphamide in the treatment of toxic epidermal necrolysis South Med J 89 1996 1001 1003
53. J.M. Friedman J.E. Polifka Teratogenic effects of drugs, a resource for clinicians 1994 John Hopkins University Press Baltimore 53 55
54. J. Gossmann H.G. Kachel W. Schoeppe Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors Transplantation 56 1993 585 589
55. J. Gossmann P. Thurmann T. Bachmann Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients Kidney Internat 50 1996 973 978
56. H. Granlund P. Erkko E. Eriksson Comparison of cyclosporine and topical betamethasone-17, 21-diproprionate in the treatment of severe chronic hand eczema Acta Derm Venereol (Stockh) 76 1996 371 376
57. H. Granlund P. Erkko M. Sinisalo Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy Br J Dermatol 132 1995 106 112
58. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines Guidelines for monitoring drug therapy in rheumatoid arthritis Arthritis Rheum 39 1996 723 731
59. J.C. Guillaume L. Vaillant P. Bernard Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid Arch Dermatol 129 1993 49 53
60. W.P. Gulliver G.F. Murphy V.A. Hannaford Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin Br J Dermatol 48 1996 35 39
61. V. Hamuryudan Y. Ozyazgan N. Hizli Azathioprine in Behcet's syndrome: effects on long-term prognosis Arthritis Rheum 40 1997 769 774
62. M. Haselberger T. Schwinghammer Efficacy of mesna for the prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy Ann Pharmacother 29 1995 918 920
63. R.A. Hemendinger S.E. Bloom Selective mitomycin C and cyclophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo Immunopharmacol 35 1996 71 82
64. M.C.Y. Heng S.G. Allen Efficacy of cyclophosphamide in toxic epidermal necrolysis J Am Acad Dermatol 25 1991 778 786
65. V. Ho Cyclosporine in the treatment of generalized granuloma annulare [letter] J Am Acad Dermatol 33 1995 298
66. V. Ho M.A.R. Cloutier D. Gratton Neoral in the treatment of psoriasis: Consensus treatment guidelines J Cutan Med Surg 1 1997 209 215
67. V.C. Ho D.M. Zloty Immunosuppressive agents in dermatology Dermatol Clin 11 1993 73 85
68. T. Itoh H. Hosokawa Y. Shirai Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide Br J Dermatol 134 1996 931 933
69. E.W.B. Jeffes III J.L. McCullough M.R. Pittelkow Methotrexate therapy of psorisas: Differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate J Invest Derm 104 1995 183 188
70. O.W. Kamel L.M. Weiss van de Rijn M. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy Am J Surg Path 20 1996 1279 1287
71. J.S. Kasteler J.P. Callen Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis J Am Acad Dermatol 36 1997 67 71
72. L.R. Klein J.P. Callen Azathioprine: effective steroid-sparing therapy for generalized lichen planus South Med J 85 1992 198 201
73. S. Knowles A. Gupta N. Shear Azathioprine hypersensitivity-like reactions—a case report and review of the literature Clin Exp Dermatol 20 1995 353 356
74. J.M. Kremer The mechanism of action of methotrexate in rheumatoid arthritis: the search continues J Rheumatol 21 1994 1 5
75. J.M. Kremer G.S. Alarcon R.W. Lightfoot Jr Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity Arthritis Rheum 37 1994 316 328
76. C. Laburte R. Grossman J. Abi-Rached Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis Br J Dermatol 130 1994 366 375
77. J.T. Lear J.S. English Erosive and generalized lichen planus responsive to azathioprine Clin Exp Dermatol 21 1996 56 57
78. J.T. Lear J.S. English P. Jones Retrospective review of the use of azathioprine in severe atopic dermatitis J Am Acad Dermatol 35 1996 642 643
79. J.T. Lear J.S. English A.G. Smith Nodular prurigo responsive to azathioprine [letter] Br J Dermatol 134 1996 1151
80. L. Lennard C. Harrington M. Wood Metabolism of azathioprine to 6-thioguanine nucleotides in patients with pemphigus vulgaris Br J Clin Pharmacol 23 1987 229 233
81. L. Lennard C. Rees J. Lilleyman Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolism and neutropenia Br J Clin Pharmacol 16 1983 359 363
82. G.C. Liang A.S. Granston Complete remission of multicentric reticulohistiocytosis with combination therapy of steroid, cyclophosphamide, and low-dose pulse methotrexate. Case report, review of the literature, and proposal for treatment [Review] Arthritis Rheum 39 1996 171 174
83. K.K. Lim W.P. Su A.L. Schroeter Cyclosporine in the treatment of dermatologic disease: an update Mayo Clin Proc 71 1996 1182 1191
84. J. Liu FK506 and cyclosporin, molecular probes for studying intracellular signal transduction Immunol Today 14 1993 290 295
85. N.J. Lowe J.M. Weider A. Rosenbach Long-term low-dose cyclosporine therapy for psoriasis: Effects on renal function and structure J Am Acad Dermatol 35 1996 710 719
86. G. Mahrle H.J. Schulze M. Brautigam Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study Br J Dermatol 135 1996 752 757
87. J. Marcinkiewicz K. Bryniarski W. Ptak Cyclophosphamide uncovers two separate macrophage subpopulations with opposite immunogenic potential and different patterns of monokine production Cytokine 6 1994 472 477
88. A. Masala R. Faedda S. Alagna Use of testosterone to prevent cyclophosphamide-induced azoospermia Ann Int Med 126 1997 292 295
89. C.J. McDonald Cytotoxic agents for use in dermatology I J Am Acad Dermatol 12 1985 753 775
90. N. Mobini T. Padilla Jr A.R. Ahmed Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine J Am Acad Dermatol 36 1997 264 266
91. K.G. Moder A. Tefferi M.D. Cohen Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study Am J Med 99 1995 276 281
92. M.J. Moore Clinical pharmacokinetics of cyclophosphamide Clin Pharmacokinet 20 1991 194 208
93. E.A. Olsen The pharmacology of methotrexate J Am Acad Dermatol 25 1991 306 318
94. S.L. Olsen D.G. Renlund J.B. O'Connell Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole Transplantation 56 1993 359 362
95. B.E. Ostrov B.H. Athreya A.H. Eichenfield Successful treatment of severe cytophagic histiocytic panniculitis with cyclosporine A Sem Arthritis Rheum 25 1996 404 413
96. A.G. Pandya K.J. Warren P.R. Bergstresser Cicatricial pemphigoid successfully treated with pulse intravenous cyclophosphamide [letter] Arch Dermatol 133 1997 245 247
97. J.S. Pasricha B.K. Khaitan Curative treatment for pemphigus [letter] Arch Dermatol 132 1996 1518 1519
98. C. Paul A. LeTourneau J.M. Cayuela Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis Arch Dermatol 133 1997 867 871
99. M.A. Paul J.L. Jorizzo A.J. Fleischer Low-dose methotrexate treatment in elderly patients with bullous pemphigoid J Am Acad Dermatol 31 1994 620 625
100. H.P. Pearce B.B. Wilson Erosion of psoriatic plaques: An early sign of methotrexate toxicity. [Review] J Am Acad Dermatol 35 1996 835 838
101. Y. Pei Chronic cyclosporine nephrotoxicity in rheumatoid arthritis J Rheumatol 23 1996 4 5
102. Y. Pei J.W. Scholey A. Katz Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine Am J Kidney Dis 23 1994 528 536
103. I. Penn Cancers in cyclosporine-treated versus azathioprine-treated patients Transpl Proc 28 1996 876 878
104. M. Petrazzuoli M.J. Rothe C. Grin-Jorgensen Monitoring patients taking methotrexate for hepatotoxicity J Am Acad Dermatol 31 1994 969 977
105. P.D. Pigatto E. Gibelli R. Ranza Methotrexate in psoriatic polyarthritis Acta Derm Venereol (Stockh) 74 1994 114 115
106. A.V. Powles T. Cook B. Hulme Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis Br J Dermatol 128 1993 159 165
107. B.D. Pryor S.G. Bologna L.E. Kahl Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus Arthritis Rheum 39 1996 1475 1482
108. C.D. Radis L.E. Kahl G.L. Baker Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study Arthritis Rheum 38 1995 1120 1127
109. G. Rivier M.A. Khamashta G.R. Hughes Warfarin and azathioprine: a drug interaction does exist [letter] Am J Med 95 1993 342
110. H.H. Roenigk Jr R. Auerbach H.I. Maibach Methotrexate in psoriasis: Revised guidelines J Am Acad Dermatol 19 1988 145 156
111. D. Rosenthal L. Guenther J. Kelly Current thoughts on the use of methotrexate in patients with psoriasis J Cutan Med Surg 2 1997 41 46
112. H. Rothe V. Burkart A. Faust Interleukin-12 gene expression mediates the accelerating effect of cyclophosphamide in autoimmune disease Ann N Y Acad Sci 795 1996 397 399
113. M.J. Rothe C. Grin-Jorgensen W.H. Ramsey Monitoring patients taking methotrexate J Am Acad Dermatol 32 1995 680
114. T. Ruzicka Cyclosporin in less common immune-mediated skin diseases [Review] Br J Dermatol 48 1996 40 42
115. P.A. Saway L.W. Heck J.R. Bonner Azathioprine hypersensitivity Am J Med 84 1988 960 964
116. E. Schutz J. Gummert F. Mohr Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine? Therap Drug Monit 18 1996 228 233
117. J. Shapiro H. Lui V. Tron Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: A clinical and immunopathologic evaluation J Am Acad Dermatol 36 1997 114 117
118. G. Singh J.F. Fries P. Spitz Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective Arthritis Rheum 32 1989 837 843
119. J. Snow L. Gibson A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatology patients J Am Acad Dermatol 32 1995 114 116
120. R.S. Stern N. Laird The carcinogenic risk of treatments for severe psoriasis Cancer 73 1994 2759 2764
121. T.J. Stillwell R.C. Benson Jr Cyclophosphamide-induced hemorrhagic cystitis—a review of 100 patients Cancer 61 1988 451 457
122. W.C. Talar Y.M. Hijazi M.M. Walther Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis Ann Int Med 124 1996 477 484
123. B.B. Tan J.T. Lear D.J. Gawkrodger Azathioprine in dermatology: a survey of current practice in the U.K Br J Dermatol 136 1997 351 355
124. A.D. Teitel Treatment of pyoderma gangrenosum with methotrexate Cutis 57 1996 326 328
125. P.C.M. van de Kerhof M.J.M. de Rooij Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance Br J Dermatol 136 1997 275 278
126. J.W. van der Pijl J.N. Bouwes Bavinck J.W. de Fijter Isotretinoin and azathioprine: a synergy that makes hair curl? [letter] Lancet 348 1996 622 623
127. R.J. van Dooren-Greebe A.L. Kuijpers J. Mulder Methotrexate revisited: Effects of long-term treatment in psoriasis Br J Dermatol 130 1994 204 210
128. E. Vesell Therapeutic lessons from pharmacogenetics [editorial] Ann Intern Med 126 1997 653 655
129. L. Villalba E.M. Adams Update on therapy for refractory dermatomyositis and polymyositis [Review] Curr Opin Rheumatol 8 1996 544 551
130. P. von denDriesch C. Steffan A. Zöbe Sweet's syndrome—therapy with cyclosporin Clin Exp Dermatol 19 1994 274 277
131. E.C. Vonderheid A. Sajjadian M.E. Kadin Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders J Am Acad Dermatol 34 1996 470 481
132. V.P. Werth Pulse intravenous cyclophosphamide for treatment of autoimmune blistering disease. Is there an advantage over oral routes? [editorial] Arch Dermatol 133 1997 229 230
133. Q. Whiting-O'Keefe K.H. Fye K.D. Sack Methotrexate and histologic hepatic abnormalities: A meta-analysis Am J Med 90 1991 711 716
134. R.L. Wong C.M. Winslow K.D. Cooper The mechanisms of action of cyclosporin A in the treatment of psoriasis [Review] Immunol Today 14 1993 69 74
135. C.H. Yarboro R. Wesley M.A. Amantea Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis Ann Pharmacother 30 1996 752 755
136. C. Yates E. Krynetski T. Loennechen Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance Ann Intern Med 126 1997 608 614
137. H. Yazici H. Pazarli C.G. Barnes A controlled trial of azathioprine in Behçet's syndrome N Engl J Med 322 1990 281 285
138. H. Zachariae H. Sogaard L. Heickendorff Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies—a further 10-year followup Dermatology 192 1996 343 346
139. I. Zaki S. Patel R. Reed Toxic epidermal necrolysis associated with severe hypocalcemia, and treated with cyclosporin [letter] Br J Dermatol 133 1995 337 338
140. V. Zeller P. Cohen A.M. Prieur Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm follow-up of 6 cases J Rheumatol 23 1996 1424 1427
141. I.M. Zonneveld W.K. Bakker P.F. Dijkstra Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis Arch Dermatol 132 1996 184 187